A mutiple dose, randomized, double-blind, placebo-controlled study of subcutaneous AMG 108 in patients with type 2 diabetes mellitus.

Trial Profile

A mutiple dose, randomized, double-blind, placebo-controlled study of subcutaneous AMG 108 in patients with type 2 diabetes mellitus.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2009

At a glance

  • Drugs MEDI 8968 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2009 Actual initiation date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 05 Feb 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top